Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity?
Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity?
复制标题
DOI：
10.1177/0961203308096068
复制
发表时间：
2009-03-01
期刊：
影响因子：
2.6
通讯作者：
Blanco, J.
中科院分区：
文献类型：
--
作者：
De La Torre, M.;Urra, J. M.;Blanco, J.
糖蛋白gp 130是IL-6受体膜结构域的信号转导亚基。此外，gp 130在IL-6超家族的受体中是共有的，并且它在通过这些受体产生信号转导中起关键作用。该研究的目的是评估系统性红斑狼疮（SLE）患者TCD 4（+）和B细胞上IL-6超家族受体分子gp 130的表达。SLE患者外周血T淋巴细胞4+和B淋巴细胞表面gp 130的表达率分别为2.79%和8.36%，高于健康对照组的0.36%和0.37%。活动期狼疮患者B细胞亚群中gp 130的表达（复发15.1%，新发26.6%）高于稳定期狼疮患者（2.83%），而T细胞CD 4淋巴细胞中gp 130的表达无明显差异。当疾病的活动性在重新调整其免疫抑制治疗后消失时，观察到B淋巴细胞上gp 130表达的显著降低（20.8-3.8%）。此外，疾病活动性（如系统性红斑狼疮疾病活动指数评分）与淋巴细胞B表面gp 130表达之间存在显著相关性（r（s）= 0.5880，P = 0.0002）。根据我们的结果和ROC曲线分析，以6.7%的B细胞表达gp 130为界值，区分活动期和稳定期SLE的敏感性为0.93，特异性为0.75。结论：SLE患者存在gp 130表达的改变。疾病活动性以及免疫治疗似乎会影响SLE患者B细胞亚群上gp 130的表达模式。Lupus（2009）18，216-222.
The glycoprotein gp130 is a signal traducing subunit with a membrane domain of the IL-6 receptor. In addition, gp130 is shared among the receptors for IL-6 superfamily, and it is critically involved in generating signal transduction through these receptors. The aim of the study is to evaluate the expression of the IL-6 superfamily receptor molecule gp130 on TCD4(+) and B cells in patients with systemic lupus erythematosus (SLE). Surface expression of gp130 on TCD4+ and B lymphocytes was higher in patients with SLE than in healthy controls (2.79 vs 0.36% and 8.36 vs 0.37%, respectively). Patients with active lupus had higher expression of gp130 ( relapsed 15.1%, new onset 26.6%) than stable patients (2.83%), in B-cell subset, but not in TCD4 lymphocytes. An important reduction in the gp130 expression on B lymphocytes was observed when the activity of the disease had disappeared after readjusting its immunosuppressive treatment (20.8-3.8%). In addition, there was significant correlation between the activity of the disease, measured like systemic lupus erythematosus disease activity index score, and surface expression of gp130 in lymphocytes B (r(s) = 0.5880, P = 0.0002). According with our results and roc curve analysis, a cut-off in 6.7% of B cells with gp130 expression were defined, who discriminates active/stable SLE with a sensitivity of 0.93 and a specificity of 0.75. In conclusion, there is an altered expression of gp130 in the patients with SLE. The disease activity as well as immunotherapy seems to influence the pattern of expression of gp130 on B-cell subsets in patients with SLE. Lupus (2009) 18, 216-222.